Edition:
United States

Mersana Therapeutics Inc (MRSN.OQ)

MRSN.OQ on NASDAQ Stock Exchange Global Select Market

17.48USD
15 Dec 2017
Change (% chg)

$-0.50 (-2.78%)
Prev Close
$17.98
Open
$17.94
Day's High
$18.71
Day's Low
$17.12
Volume
376,597
Avg. Vol
22,639
52-wk High
$21.01
52-wk Low
$12.75

Latest Key Developments (Source: Significant Developments)

Mersana announces third quarter loss of $0.35 per share
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - Mersana Therapeutics Inc :Mersana announces third quarter 2017 financial results and provides business updates.Qtrly ‍loss per share $0.35​.Cash, cash equivalents and marketable securities as of Sept 30, 2017 were $133.4 million, compared with $100.3 million as of Dec 31, 2016​.Expects that cash, cash equivalents and marketable securities will enable it to fund operating plan through at least mid-2019​.  Full Article

Mersana announces FDA clearance of IND application for XMT-1536
Monday, 30 Oct 2017 07:30am EDT 

Oct 30 (Reuters) - Mersana Therapeutics Inc :Mersana announces FDA clearance of IND application for XMT-1536, a first-in-class antibody drug conjugate targeting NaPi2b.‍U.S. FDA cleared company's investigational new drug application to begin phase 1 clinical trials for XMT-1536​.  Full Article

Mersana Q2 loss per share $6.33
Friday, 11 Aug 2017 07:00am EDT 

Aug 11 (Reuters) - Mersana Therapeutics Inc :Mersana announces second quarter 2017 financial results and provides business updates.Q2 loss per share $6.33.Q2 earnings per share view $-0.69 -- Thomson Reuters I/B/E/S.Mersana therapeutics - ‍expects cash, cash equivalents and marketable securities will enable it to fund its operating plan through at least mid-2019..Mersana therapeutics - ‍cash, cash equivalents and marketable securities as of june 30, were $77.2 million, compared with $100.3 million as of december 31, 2016​.Mersana therapeutics inc - qtrly ‍collaboration revenue $3.7 million versus $6.2 million​.Q2 earnings per share view $-0.69, revenue view $3.9 million -- Thomson Reuters I/B/E/S.  Full Article

Rock Springs Capital Management reports 6.8 pct passive stake in Mersana Therapeutics as of June 28, 2017
Friday, 7 Jul 2017 04:41pm EDT 

July 7 (Reuters) - Rock Springs Capital Management LP: :Rock Springs Capital Management LP reports a 6.8 percent passive stake in Mersana Therapeutics Inc as of June 28, 2017 - sec filing.  Full Article

Mersana Therapeutics sees IPO of 5 mln shares priced between $14 and $16
Friday, 16 Jun 2017 06:07am EDT 

June 16 (Reuters) - Mersana Therapeutics Inc ::Mersana Therapeutics Inc sees IPO of 5 million shares priced between between $14.00 and $16.00 - SEC filing.  Full Article

BRIEF-Mersana Announces First Patient Dosed With XMT-1536 In Phase 1 Study In Patients With NaPi2b-Expressing Tumors

* MERSANA ANNOUNCES FIRST PATIENT DOSED WITH XMT-1536 IN PHASE 1 STUDY IN PATIENTS WITH NAPI2B-EXPRESSING TUMORS Source text for Eikon: Further company coverage: